Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Stock data | 2024 | Change |
---|---|---|
Price | $8.16 | N/A |
Market Cap | $247.81M | N/A |
Shares Outstanding | 30.37M | N/A |
Employees | 87.00 | N/A |